&w=3840&q=100){kind=logo}
How much money the BCCI earned in FY24, with IPL as its biggest cash cow
The BCCI earned over Rs 9,000 crore in FY24 with IPL as its biggest money maker. Reuters/AFP
The Indian Premier League (IPL) continues to be the biggest money-maker for the Board of Control for Cricket in India (BCCI). According to a report in The Hindu, which quoted Rediffusion, the IPL contributed more than 59 percent of BCCI's total revenue in FY24, proving once again why it is called the Board's cash cow.
Here's how much money BCCI made in FY24
In total, BCCI reportedly earned Rs. 9,741.7 crore (over $1 billion) in FY23–24, out of which Rs 5,761 crore (over $580 million) came from the IPL alone. Apart from IPL, the Women's Premier League (WPL), international media rights, and sponsorship deals also added to the board's income.
The report also mentioned that BCCI made Rs 361 crore from non-IPL media rights, like broadcasting India's international matches. Apart from these, the Board has close to Rs 30,000 crore in reserves, earning nearly Rs 1,000 crore a year in interest alone. The board also gets Rs 1,000 crore from the ICC as annual revenue.
STORY CONTINUES BELOW THIS AD
Business strategist Lloyd Mathias said IPL is a perfect model for generating money and giving opportunities to players from the domestic level.
'BCCI in 2007 discovered a golden goose – the IPL which is now a 100 per cent part of the BCCI. The tournament is the best and media rights are constantly going up. IPL also ensures that players from Ranji Trophy-levelget a playing field. IPL will continue to churn out profitability as it growth further,' Mathias said.
Sandeep Goyal, Chief of Rediffusion, said that even tournaments like Ranji Trophy and Duleep Trophy can be commercialised to boost non-IPL income. He believes BCCI's overall revenue could grow 10 to 12 percent every year, thanks to sponsorships, media deals, and match-day earnings.
'BCCI has immense potential to commercialise traditional formats like Ranji Trophy, Duleep Trophy, or CK Nayudu Trophy to shore up non-IPL revenues. Moreover, the board has close to ₹30,000 crore in reserves, which brings in about ₹1,000 crore a year in interest alone. These revenues aren't just sustainable—they are poised to grow 10–12 per cent annually, thanks to expanding sponsorships, media deals, and matchday earnings,' Sandeep Goyal said.
However, experts also warned that BCCI relies too much on IPL. A disruption in the league can hurt revenue. For example, the tournament was briefly halted this year due to Operation Sindoor and the subsequent tensions between India and Pakistan. For now, the IPL remains the most crucial brand for the BCCI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
28 minutes ago
- Indian Express
JERC pulls up CPDL, CED over delay in refunding excess meter rentals
The Joint Electricity Regulatory Commission (JERC) has issued a show-cause notice to the Chandigarh Power Distribution Limited (CPDL) and the Chandigarh Electricity Department (CED) for failing to implement orders directing the refund of wrongly charged meter rentals to city consumers. The notice, dated July 17, 2025, warns that unless both agencies reply within two weeks, JERC will initiate proceedings under Section 142 of the Electricity Act, 2003. It follows repeated reminders by the Electricity Ombudsman, who upheld a Consumer Grievances Redressal Forum (CGRF) order on April 16, 2025, in favour of the Indian Citizens Forum (ICF). The ombudsman had directed CED and CPDL to refund excess meter rentals collected over 16 months with interest at the base rate of the State Bank of India, correct all bills within 15 days, and pay consumers Rs 100 per day for delays beyond the stipulated period. It also required the agencies to submit a compliance report within 30 days. Despite the order, refunds have not yet reached consumers, a delay of nearly four months that the ombudsman warned could amount to contempt. The ICF delegation, led by president S K Nayar and secretary Narinder Sharma, met CPDL director Arun Kumar Verma and general manager M P Singh on Wednesday, pressing for immediate refunds. Verma assured the forum that CPDL would process refunds through upcoming bills as soon as it receives the final list of affected consumers from CED. The ICF leaders said they would continue to monitor the issue. 'Consumers cannot be made to wait endlessly for what is rightfully theirs,' Nayar said, adding that further delays would leave the regulator with 'no option but to act'.
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Tilaknagar Industries to acquire Imperial Blue business for 412.6 mn euro
Tilaknagar Industries has entered into a definitive agreement to acquire the Imperial Blue business division from Pernod Ricard India via slump sale for a lump-sum consideration based on an enterprise value of 412.6 million euro (approximately Rs 4,150 crore as on date), the company said in a stock exchange filing. The consideration includes a deferred payment of 28 million euro (approximately ₹282 crore as on date), to be paid four years after the closure of the transaction. The proposed transaction includes the acquisition of the Imperial Blue brand, which recorded sales of 22.4 million 9-litre cases for the year ended March 2025 across India and other markets. It also includes two owned units and services from co-manufacturing bottlers across India, the filing said. The transaction is subject to approval from the Competition Commission of India, with closure anticipated in about six months from the signing of the definitive agreement. Tilaknagar Industries will raise a mix of debt and equity to finance the acquisition. Imperial Blue will act as Tilaknagar Industries' launchpad for a significant whisky premiumisation journey, enabling the company to build a strong whisky portfolio across premium price points. 'We're excited to build on Imperial Blue's strong foundation and take it to new heights,' Dahanukar added. Imperial Blue is the third-largest whisky brand in India by volume, with over 25 years of brand heritage. The underlying business reported revenue of Rs 3,067 crore for the year ended March 2025, the company said in its release. 'This landmark acquisition, the largest in the Indian alcoholic beverages space by an Indian company, fast-tracks Tilaknagar Industries' foray into the whisky segment, the largest IMFL (Indian Made Foreign Liquor) category in India. It also significantly expands Tilaknagar Industries' distribution reach, reinforcing its evolution into a truly pan-India player with strong scale across both brandy and whisky, with a combined volume of 34 million 9-litre cases for the year ended March,' the filing added.
Economic Times
28 minutes ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
